A 26-week, randomized trial of insulin detemir versus NPH insulin in children and adolescents with type 2 diabetes (iDEAt2)

European Journal of Pediatrics
Mark D WheelerNehama Zuckerman-Levin

Abstract

There are limited studies evaluating the safety and efficacy of treatments in young people with type 2 diabetes (T2D). This study compared the efficacy and safety of insulin detemir versus neutral protamine Hagedorn (NPH) insulin, both in combination with metformin and lifestyle intervention, in children and adolescents with T2D. This randomized, open-label, phase 3 trial recruited patients (n = 42) aged 10-17 years diagnosed with T2D already receiving metformin ± other oral antidiabetic drugs ± basal insulin. Patients were randomized (1:1) to receive either insulin detemir or NPH insulin, both with the maximum tolerated dose of metformin, and lifestyle intervention, over 26 weeks. Enrollment terminated prematurely after 17 months due to a very slow recruitment rate (12% of the target met). After 26 weeks, the observed mean HbA1c value had decreased by 0.61% points in the insulin detemir group vs. 0.84% points in the NPH insulin group. The rate of symptomatic blood glucose-confirmed hypoglycemic episodes was 0.4 episodes/patient-year of exposure (PYE) for insulin detemir vs. 1.1 episodes/PYE for NPH insulin. No safety issues were revealed with either basal insulin. Due to the low number of patients recruited, no efficacy conclu...Continue Reading

References

Mar 4, 2000·The Journal of Pediatrics·T K YoungP Wood-Steiman
Oct 14, 2009·International Journal of Obesity : Journal of the International Association for the Study of Obesity·UNKNOWN TODAY Study Group
May 12, 2010·Pediatric Diabetes·Julie Anne L GemmillKristina I Rother
May 1, 2012·The New England Journal of Medicine·UNKNOWN TODAY Study GroupFrancine Kaufman
May 25, 2013·Diabetes Care·William V Tamborlane, Georgeanna Klingensmith
Oct 29, 2013·The Journal of Adolescent Health : Official Publication of the Society for Adolescent Medicine·Tammy T NguyenKristina I Rother
May 6, 2014·JAMA : the Journal of the American Medical Association·Dana DabeleaUNKNOWN SEARCH for Diabetes in Youth Study
Jun 6, 2014·Diabetes·Jean M LawrenceUNKNOWN SEARCH for Diabetes in Youth Study Group
Sep 4, 2014·Pediatric Diabetes·Phil ZeitlerUNKNOWN International Society for Pediatric and Adolescent Diabetes
Oct 9, 2015·Annals of the New York Academy of Sciences·Tamara S Hannon, Silva A Arslanian
Oct 12, 2016·Primary Care Diabetes·Kamlesh Khunti, David Millar-Jones
Apr 14, 2017·The New England Journal of Medicine·Elizabeth J Mayer-DavisUNKNOWN SEARCH for Diabetes in Youth Study

❮ Previous
Next ❯

Citations

Aug 24, 2021·Expert Opinion on Pharmacotherapy·Magnus F G GrøndahlFilip K Knop
Sep 24, 2021·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Brooke M CurrieJoseph A Johnston

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02131272

Software Mentioned

TODAY

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Related Papers

Diabetic Medicine : a Journal of the British Diabetic Association
N ThalangeV Peterkova
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
de Arellano A RamírezL Lizán
Diabetic Medicine : a Journal of the British Diabetic Association
K J RobertsonJ Ludvigsson
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
de Arellano A RamírezLuis D De
Diabetic Medicine : a Journal of the British Diabetic Association
HOE 901/2004 Study Investigators Group
© 2022 Meta ULC. All rights reserved